keyword
https://read.qxmd.com/read/34331612/lncrna-hcp5-acts-as-a-mir-128-3p-sponge-to-promote-the-progression-of-multiple-myeloma-through-activating-wnt-%C3%AE-catenin-cyclin-d1-signaling-via-plagl2
#1
Qinhua Liu, Ruonan Ran, Mingyue Song, Xiaodan Li, Zhengsheng Wu, Guanrong Dai, Ruixiang Xia
BACKGROUND: Although long non-coding RNA (lncRNA) HCP plays essential roles in human cancers, its function and mechanism in multiple myeloma (MM) have not crystallized. METHODS: HCP5 level in MM was assessed through qRT-PCR. A series of functional investigations were conducted to evaluate the influences of HCP5 on proliferation and apoptosis. Bioinformatics analysis and RIP/RNA pull-down assays were carried out to determine the relationships among HCP5, miR-128-3p, and PLAGL2...
July 31, 2021: Cell Biology and Toxicology
https://read.qxmd.com/read/34331266/implementation-of-a-pregnancy-prevention-programme-ppp-with-a-controlled-distribution-system-cds-for-the-generic-teratogenic-phthalimides-thalidomide-lenalidomide-and-pomalidomide
#2
REVIEW
Marion Mueller, David J Lewis
Thalidomide (α-phthalimidoglutaride) was marketed in the 1950s and early 1960s; it was promoted as a sedative-hypnotic agent with minimal hangover. It was available in some countries as an over-the-counter medicine. Publications reporting profound teratogenic effects with thalidomide brought about major revisions to the monitoring of the safety of medicines. As a consequence of previously unrecognised teratogenic effects, it has been estimated that over 12,000 children were born with a range of defects and disabilities, including severe congenital anomalies...
July 30, 2021: Therapeutic Innovation & Regulatory Science
https://read.qxmd.com/read/34330674/risk-of-non-hodgkin-s-lymphoma-in-hcv-patients-in-the-united-states-between-2013-and-2020-a-population-based-study
#3
Akram Alkrekshi, Ahmad Kassem, Changsu Park, William Tse
Hepatitis C virus (HCV) is a significant healthcare problem affecting ~1% of the United States population. Meta-analyses of epidemiological studies reported a strong association between non-Hodgkin's lymphoma (NHL) and HCV. Direct oncogenic properties of HCV proteins and chronic antigenic stimulation are possible etiologies. We explored if NHL's prevalence has changed since older HCV therapy based on interferon that shared antiviral and anti-lymphoma properties was replaced with interferon-free direct-acting antivirals (DAA)...
June 24, 2021: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/34330673/primary-mediastinal-b-cell-lymphoma-a-2021-update-on-genetics-diagnosis-and-novel-therapeutics
#4
REVIEW
Zahoor Ahmed, Safa Saadat Afridi, Zeryab Shahid, Zarlakhta Zamani, Sana Rehman, Wajeeha Aiman, Maryam Khan, Muhammad Ayaz Mir, Farrukh T Awan, Faiz Anwer, Raheel Iftikhar
Primary mediastinal large B-cell lymphoma (PMBCL) is an aggressive B-cell lymphoma arising from thymic B-cells having clinicopathologic features distinct from systemic diffuse large B-cell lymphoma (DLBCL). PMBCL comprises 2% to 4% of all non-Hodgkin lymphomas (NHL), 7% of DLBCL and seen predominantly in young females with a median age of 35 years at diagnosis. The annual incidence of PMBCL is 0.4 per million with a 5-year survival rate exceeding 70% with improving supportive care and genetic characterization of the disease...
June 24, 2021: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/34330018/endogenous-soluble-receptors-sbcma-and-staci-biomarker-immunoregulator-and-hurdle-for-therapy-in-multiple-myeloma
#5
REVIEW
Edgar Meinl, Markus Krumbholz
BAFF and APRIL regulate B cell homeostasis by binding to their three receptors BAFFR, BCMA and TACI. The complexity of this system is further increased by shedding of these three receptors; this reduces signaling due to the display of less surface receptors. Further, soluble forms, sBCMA and sTACI, were detected in body fluids and serve as biomarker in malignancies, autoimmune diseases and immunodeficiencies. sBCMA and sTACI function as decoys blocking BAFF and APRIL. BCMA is a promising therapeutic target in multiple myeloma, but sBCMA may reduce therapeutic activity of CAR T cells, bispecific antibodies, and antibody-drug conjugates...
July 27, 2021: Current Opinion in Immunology
https://read.qxmd.com/read/34327896/-research-progress-in-the-rapid-preparation-of-monoclonal-antibodies-of-mouse-hybridoma
#6
Shuiqin Fang, Cheng Liu, Junfei Ma, Shuaishuai Yan, Dongpo Xu, Qing Liu
Mouse hybridoma monoclonal antibody is the most commonly used antibody in immunology because of its stable source, easy preparation in later stage and high yield. The traditional time-consuming and laborious hybridoma preparation technology could not meet the growing market demand. In this paper, we describe the rapid preparation techniques involved in antigen design and screening, B cell enrichment and screening, transgenic myeloma cells, fusion technology improvement, positive hybridoma cell screening and rapid detection of monoclonal antibody performance, to provide a reference for rapid preparation of mouse hybridoma monoclonal antibody...
July 25, 2021: Sheng Wu Gong Cheng Xue Bao, Chinese Journal of Biotechnology
https://read.qxmd.com/read/34327809/prl-3-promotes-a-positive-feedback-loop-between-stat1-2-induced-gene-expression-and-glycolysis-in-multiple-myeloma
#7
Caroline N Smith, Jessica S Blackburn
Over 34 000 patients are diagnosed yearly with multiple myeloma (MM), which remains a fatal malignancy. Expression of the phosphatase PRL-3 is associated with poor prognosis in MM patients, and Vandsemb et al. have demonstrated that PRL-3 contributes to enhanced MM cell fitness through activation of a glycolysis-associated feedback loop. PRL-3 resulted in increased expression of signal transducer and activator of transcription 1 (STAT1) and 2 (STAT2) and increased glycolysis. Increased glucose metabolism in turn activated STAT1/2 and interferon 1-related genes...
July 29, 2021: FEBS Journal
https://read.qxmd.com/read/34326757/hyperviscosity-retinopathy-and-immunogammopathy-maculopahy-as-new-onset-of-multiple-myeloma
#8
Natasha Ferreira Santos da Cruz, José Arthur Pinto Milhomens Filho, Desirée Mayara Nery Ferraro, Murilo Ubukata Polizelli, Nilva Simeren Bueno de Moraes Ambrogini
The purpose is to report a case of immunogammopathy maculopathy and hyperviscosity retinopathy as the presenting feature of new-onset multiple myeloma (MM) in an otherwise healthy man. A 50-years-old man presented with painless visual changes in both eyes for 2 months. Ocular examination revealed bilateral CRVO-like associated with macular edema (ME) and an inferior serous detachment. Hematologic investigation revealed an increased percentage of plasma cells in the bone marrow, reaching the diagnosis of MM IgM/kappa...
May 2021: Case Reports in Ophthalmology
https://read.qxmd.com/read/34326466/response-to-mrna-vaccination-for-covid-19-among-patients-with-multiple-myeloma
#9
Samuel D Stampfer, Marissa-Skye Goldwater, Scott Jew, Sean Bujarski, Bernard Regidor, David Daniely, Haiming Chen, Ning Xu, Mingjie Li, Tracy Green, Eddie Fung, Elias Aquino, Regina Swift, Shahrooz Eshaghian, Kurt Preugschat, Aaron J Feinstein, Tanya M Spektor, James R Berenson
Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination response against SARS-CoV-2 is unknown. Thus, we analyzed responses to mRNA vaccination against COVID-19 among these patients. Using an ELISA-based assay that detects IgG antibodies to SARS-CoV-2 spike protein, we determined serum antibody levels prior to immunization and 12-21 and 14-21 days following the first and second vaccinations, respectively, with mRNA-1273 (Moderna) or BNT162b2 (Pfizer/BioNTech) among 103 MM patients (96 and 7 with active and smoldering disease, respectively)...
July 29, 2021: Leukemia
https://read.qxmd.com/read/34326035/clinical-characteristics-treatment-and-evolution-of-splenic-and-nodal-marginal-zone-lymphomas-retrospective-and-multicentric-analysis-of-portuguese-centers
#10
Catarina Dantas Rodrigues, Rita Pinho Peixeiro, Diana Viegas, Pedro Chorão, M Eduarda Couto, Cátia Lino Gaspar, João Paulo Fernandes, Daniela Alves, Lídia Alves Ribeiro, Pedro de Vasconcelos M, Ana Luísa Tomé, Margarida Badior, Henrique Coelho, Fernando Príncipe, Sérgio Chacim, Maria Gomes da Silva, Rita Coutinho
INTRODUCTION: Treatment of Splenic (SMZL) and Nodal (NMZL) Marginal Zone Lymphoma is not consensual. Histologic transformation (HT) to aggressive lymphoma is a poorly understood event, with an unfavorable outcome. OBJECTIVES: Describe the clinical characteristics, treatment, outcomes and incidence of HT. METHODS: Characteristics of patients with SMZL and NMZL consecutively diagnosed in 8 Portuguese centers were retrospectively reviewed. Endpoints were overall survival (OS), time to first systemic treatment (TTFST), frequency of HT and time to transformation (TTT)...
June 24, 2021: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/34325671/gastric-amyloidosis-presenting-as-acute-upper-gastrointestinal-bleeding-a-case-report
#11
Rachael Chan, Stephanie Carpentier
BACKGROUND: Amyloidosis is characterized by extracellular tissue deposition of fibrils, composed of insoluble low-molecular-weight protein subunits. The type, location, and extent of fibril deposition generates variable clinical manifestations. Gastrointestinal (GI) bleeding due to amyloid deposition is infrequent. Previous literature describes upper GI bleeding (UGIB) in patients with known amyloid disease. Here, we describe a case of recurrent UGIB that ultimately led to a diagnosis of GI amyloidosis and multiple myeloma in a patient with no history of either...
July 29, 2021: BMC Gastroenterology
https://read.qxmd.com/read/34325606/the-burden-of-skeletal-related-events-in-four-latin-american-countries-argentina-brazil-colombia-and-mexico
#12
Javier Garcia Perlaza, Rima Aziziyeh, Anna Zhou, Vitor De Sousa Barbosa, Jenny Amaya, Joaquin Caporale, Monica Elena Alva, Juan Forero, Straus Tanaka, Gaurav Suri, David Garcia
Aim: Skeletal-related events (SREs) are major bone complications that frequently occur in patients with solid tumors (ST) and bone metastases, and in patients with multiple myeloma (MM). SREs include pathological fracture, spinal cord compression, radiation to bone, and surgery to bone. Limited data are available regarding the burden of SREs in Latin America. We built an economic model to quantify the current and future economic burden of SREs among adults in four Latin American countries: Argentina, Brazil, Colombia, and Mexico...
July 29, 2021: Journal of Medical Economics
https://read.qxmd.com/read/34324647/requirements-for-operational-cure-in-multiple-myeloma
#13
Mohamad Mohty, Hervé Avet-Loiseau, Jean-Luc Harousseau
Multiple myeloma is usually considered as an incurable disease. However, with the therapeutic improvement observed in the last few years, achievement of an "operational" cure is increasingly becoming a realistic goal. The advent of novel agents, with or without high-dose chemotherapy and autologous transplantation, uncovered a correlation between the depth of response to treatment and the outcome. Of note, minimal residual disease (MRD) negativity is increasingly shown to be associated with improved progression-free survival (PFS), and MRD status is becoming a well-established and strong prognostic factor...
July 29, 2021: Blood
https://read.qxmd.com/read/34323945/crystal-storing-histiocytosis-associated-with-smoldering-myeloma
#14
Sanne J de Haart, Roos J Leguit
No abstract text is available yet for this article.
July 29, 2021: Blood
https://read.qxmd.com/read/34323266/hdac6-inhibitor-wt161-performs-antitumor-effect-on-osteosarcoma-and-synergistically-interacts-with-5-fu
#15
Consolato Sergi
An imbalance between protein aggregation and protein degradation may induce "stress" in the functionality of the endoplasmic reticulum. There are quality control mechanisms to minimize misfolding and to eliminate misfolded proteins before aggregation becomes lethal for the cell.  Proper protein folding and maturation is one of the crucial functions of the endoplasmic reticulum. Chaperones of the endoplasmic reticulum and folding enzymes guarantee correct conformational maturation of emerging secretory proteins...
July 29, 2021: Bioscience Reports
https://read.qxmd.com/read/34322992/leishmaniasis-mimicking-multiple-myeloma
#16
Ioannis Papakonstantinou, Epameinondas Koumpis, Eugenia Fytsili, Aikaterini Panteli, Haralampos Milionis, Alexandra Papoudou-Bai, Eleni Kapsali, Eleftheria Hatzimichael
No abstract text is available yet for this article.
July 29, 2021: International Journal of Laboratory Hematology
https://read.qxmd.com/read/34322356/chimeric-antigen-receptor-t-cell-therapy-and-its-significance-in-multiple-myeloma
#17
REVIEW
Jaskamal Padda, Khizer Khalid, Ujala Zubair, Mounika M Peethala, Varsha Kakani, Lakshmi Goriparthi, Abdulelah H Almanie, Ayden Charlene Cooper, Gutteridge Jean-Charles
Multiple myeloma (MM) has a five-year prevalence worldwide of 230,000 people and is known as the second most common hematological malignancy within the United States. Extensive research has been conducted to gain a wide range of treatment strategies, providing hope to these patients. Combination therapy using chemotherapy, monoclonal antibodies, and immunomodulatory drugs are the current management of choice. After the introduction of chimeric antigen receptor (CAR) T cell therapy, promising results have been evidenced...
June 2021: Curēus
https://read.qxmd.com/read/34322336/malignant-and-non-malignant-causes-of-hypercalcemia-a-retrospective-study-at-a-tertiary-care-hospital-in-pakistan
#18
Sabiha Banu, Sumera Batool, Saadia Sattar, Muhammad Q Masood
BACKGROUND: Hypercalcemia is a common electrolyte abnormality presenting with a variety of symptoms. The common causes are primary hyperparathyroidism and malignancy associated with hypercalcemia. However, iatrogenic hypercalcemia with the overzealous use of vitamin D has now emerged as another important cause of hypercalcemia over the past decade. OBJECTIVE: This study aims to evaluate the causes of hypercalcemia, management strategies, and outcomes in patients admitted with hypercalcemia in a tertiary care hospital...
June 2021: Curēus
https://read.qxmd.com/read/34322131/case-report-successful-management-of-a-refractory-plasmablastic-lymphoma-patient-with-tislelizumab-and-lenalidomide
#19
Lili Cheng, Qi Song, Mengke Liu, Yan Wang, Hongmei Yi, Ying Qian, Pengpeng Xu, Shu Cheng, Chaofu Wang, Li Wang, Weili Zhao
Plasmablastic lymphoma (PBL) is a rare and aggressive hematological malignancy. PBL commonly occurs in immune incompetent patients, such as those with human immunodeficiency virus (HIV), post-transplant status, or immunosenescence. Given its rarity, there is no specific standard treatment for PBL. However, small case series have shown that intensive chemotherapies combined with anti-myeloma agents such as bortezomib and lenalidomide were effective in treating PBL. Unfortunately, some fragile patients could not tolerate intensive chemotherapeutic regimens, especially the elderly patients...
2021: Frontiers in Immunology
https://read.qxmd.com/read/34321279/minimal-residual-disease-in-myeloma-application-for-clinical-care-and-new-drug-registration
#20
Kenneth C Anderson, Daniel Auclair, Stacey J Adam, Amit Agarwal, Melissa Anderson, Herve Avet-Loiseau, Mark Bustoros, Jessica Chapman, Dana E Connors, Ajeeta Dash, Alessandra Di Bacco, Ling Du, Thierry Facon, Juan Flores-Montero, Francesca Gay, Irene M Ghobrial, Nicole J Gormley, Ira Gupta, Howard Higley, Jens Hillengass, Bindu Kanapuru, Dickran Kazandjian, Gary J Kelloff, Ilan R Kirsch, Brandon E Kremer, Ola Landgren, Elizabeth D Lightbody, Oliver C Lomas, Sagar Lonial, Maria Victoria Mateos, Rocio Montes de Oca, Lata Mukundan, Nikhil C Munshi, Elizabeth K O'Donnell, Alberto Orfao, Bruno Paiva, Reshma Patel, Trevor J Pugh, Karthik Ramasamy, Jill Ray, Mikhail Roshal, Jeremy A Ross, Caroline C Sigman, Katie L Thoren, Suzanne Trudel, Gary A Ulaner, Nancy Valente, Brendan M Weiss, Elena Zamagni, Shaji K Kumar
The development of novel agents has transformed the treatment paradigm for multiple myeloma (MM), with minimal residual disease (MRD) negativity now achievable across the entire disease spectrum. Bone marrow-based technologies to assess MRD, including approaches using next-generation flow and next-generation sequencing, have provided real-time clinical tools for the sensitive detection and monitoring of MRD in MM patients. Complementary liquid biopsy-based assays are now quickly progressing with some, such as mass spectrometry methods, being very close to clinical use, while others utilizing nucleic acid-based technologies are still developing and will prove important to further our understanding of the biology of MRD...
July 28, 2021: Clinical Cancer Research
keyword
keyword
659
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"